Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Latanoprost and respiratory function in asthmatic patients - Randomized, double-masked, placebo-controlled crossover evaluation
Autore:
Hedner, J; Everts, B; Moller, CS;
Indirizzi:
Sahlgrens Univ Hosp, Dept Clin Pharmacol, S-41345 Gothenburg, Sweden Sahlgrens Univ Hosp Gothenburg Sweden S-41345 S-41345 Gothenburg, Sweden Pharmacia & Upjohn Inc, Stockholm, Sweden Pharmacia & Upjohn Inc Stockholm Sweden & Upjohn Inc, Stockholm, Sweden
Titolo Testata:
ARCHIVES OF OPHTHALMOLOGY
fascicolo: 10, volume: 117, anno: 1999,
pagine: 1305 - 1309
SICI:
0003-9950(199910)117:10<1305:LARFIA>2.0.ZU;2-Z
Fonte:
ISI
Lingua:
ENG
Soggetto:
OCULAR HYPOTENSIVE AGENTS; LUNG-FUNCTION TESTS; INDUCED CONTRACTION; TOPICAL TIMOLOL; SMOOTH-MUSCLE; TP-RECEPTORS; GLAUCOMA; PROSTAGLANDINS; AIRWAYS; ANALOG;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Hedner, J Sahlgrens Univ Hosp, Dept Clin Pharmacol, S-41345 Gothenburg, Sweden Sahlgrens Univ Hosp Gothenburg Sweden S-41345 thenburg, Sweden
Citazione:
J. Hedner et al., "Latanoprost and respiratory function in asthmatic patients - Randomized, double-masked, placebo-controlled crossover evaluation", ARCH OPHTH, 117(10), 1999, pp. 1305-1309

Abstract

Objective: To evaluate the effects of single and multiple administrations of the ocular hypotensive drug latanoprost on respiratory function, asthma symptoms, and use of asthma medication in patients with bronchial asthma. Methods: Twenty-four stable patients with asthma (forced expiratory volumein 1 second: 70% to 90% of predicted and a minimum of 10% reversibility after inhalation of albuterol sulfate) with no previous exposure to inhaled corticosteroids participated in this randomized, double-masked crossover trial. Patients received latanoprost, 0.005%, or placebo, 1 drop per day, in each eye during two 6-day treatment periods separated by a 2-week washout period. Acute latanoprost or placebo provocation, methacholine chloride airway reactivity, and beta(2)-stimulator reversibility tests were performed. Main Outcome Measures: Morning and evening peak expiratory flow, spirometric performance throughout treatment periods and during different provocation tests, asthma symptoms, and use of asthma medications were evaluated. Results: There were no statistically significant differences between treatments in morning and evening peak expiratory flow, scored daytime and nocturnal asthma symptoms, or daily consumption of asthma medication. During placebo provocation, there was a small increase in forced expiratory volume in1 second that was not seen during latanoprost provocation. This small difference (-0.09 L) was statistically significant but without clinical importance. Conclusions: Resting and provoked airway function and asthma symptoms wereunaffected by latanoprost treat ment in patients with asthma with no previous exposure to corticosteroids. Latanoprost can be used in patients with glaucoma and concomitant bronchial asthma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 04:09:45